← Eichor
Study identifier: NCT06910605 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Exploring Parameters of Driving Simulation in Relation to Drug Holidays in ADHD Patients

Condition: ADHD - Attention Deficit Disorder With Hyperactivity · Driving Simulator Performance · ADHD  ·  Sponsor: Stefan Lakämper

PhaseNA
Planned participants26
Who can joinAll sexes, 10 Years to no upper limit
Healthy volunteersNo

About this study

Attention deficit hyperactivity disorder (ADHD) or syndrome (ADHS) is a symptomatically defined condition that - if untreated - is linked to a significantly increased risk of traffic accidents. In a recent umbrella review, where data from reviews and meta-analyses on 21.142.129 adults was assessed, a pooled prevalence of 3.1% of ADHD in adults was estimated. Considering that globally around 1.35 million people lose their lives and more than 50 million are suffering from injuries or disabilities due to road accidents, the fraction of car accidents caused by ADHD as a risk factor is considerable and needs to be addressed. This risk is largely presumed to be caused by an elevated level of inattentiveness in affected persons. Compounds of different groups, which can be classified in stimulants - formulations of methylphenidate and amphetamine - and non-stimulants - atomoxetin, guanfacine and clonidine -, have been shown to be effective in alleviating negative effects of ADHD, including inattentiveness. Under well-established but individually managed medication regimes, affected individuals can consequently lead a largely "unirritated" life and are not subject to fundamental restriction with respect to driving anymore. In children and adolescents, documented negative effects of stimulant medication include loss of appetite and decreased growth rates. It could however be shown that short-term interruptions (weekend, school holidays, and alike), introduced to alleviate aforementio…

This description comes directly from the study's public registry record.

Talk to the study team

Stefan Lakämper, Dr. rer. nat.  ·  +41793789984  ·  stefan.lakaemper@irm.uzh.ch

Nan Li, MSc  ·  +41797283245  ·  nan.li@irm.uzh.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Division of Traffic Medicine, Institute of Forensic Medicine, University of Zurich,Zurich, ZRH, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06910605